Robert L. Fine, MD, an associate professor of Medicine at New York Presbyterian Hospital-Columbia University Medical Center, discusses the prospective phase II study of CAPTEM (capecitabine and temozolomide) for patients with neuroendocrine tumors.

Fine says the results of the trial showed tremendous responses in every neuroendocrine tumor. The treatment elicited a response rate of 45% and a stable disease rate of 52%.

Carcinoids, which represents that majority of all neuroendocrine tumors and normally have a response rate of 0%-4%, showed a 45% response rate in this study, Fine says.

Moreover, Fine points out, the CAPTEM combination is extremely nontoxic. There were no grade 4 toxicities and only 10-15% grade 3 toxicities, with the most common grade 3 toxicity being lymphopenia.

View more from the 2014 GI Cancers Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Gastrointestinal Cancers Symposium (ASCO GI)

Robert L. Fine, MD, from the Columbia University Medical Center, discusses the prospective phase II study of CAPTEM for patients with neuroendocrine tumors.

Dr. Fine on Capecitabine Plus Temozolomide for NETs